Idelalisib Monotherapy

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Protocol Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.</td>
<td>C82</td>
<td>00291a</td>
</tr>
</tbody>
</table>

ELIGIBILITY:

- Indication as above
- ECOG 0-3

EXCLUSIONS:

- Hypersensitivity to idelalisib or any of the excipients

TESTS:

Baseline tests: FBC, U&E, LFTs
Cardiac function as clinically indicated
Virology screen -Hepatitis B (HBsAg, HBcoreAb)

Hepatitis B Reactivation: All lymphoma patients should be tested for both HBsAg and HBcoreAb as per local policy. If either test is positive, such patients should be treated with lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to halting chemotherapy.

Regular tests: FBC, U&E monthly
LFTs every 2 weeks for the first three months of treatment, then as clinically indicated. Cardiac function as clinically indicated

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.
TREATMENT:
The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.
Idelalisib 150mg is taken orally, twice daily and treatment is continued until disease progression or unacceptable toxicity develops.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idelalisib</td>
<td>150mg BD</td>
<td>PO Tablets should be swallowed whole either with or without food</td>
<td>Continuous</td>
</tr>
</tbody>
</table>

If the patient misses a dose within 6 hours of the time it is usually taken, the patient should take missed dose as soon as possible and resume the normal dosing schedule.
If the patient misses a dose by more than 6 hours, the patient should not take the missed dose and should simply resume the usual dosing schedule.

Idelalisib is available as 100mg and 150mg tablets

DOSE MODIFICATIONS:
- Any dose modification should be discussed with a Consultant

Haematological:

<table>
<thead>
<tr>
<th>ANC 1 to &lt; 1.5 x 10^9/L</th>
<th>ANC 0.5 to &lt; 1 x 10^9/L</th>
<th>ANC &lt; 0.5 x 10^9/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintain Idelalisib dosing</td>
<td>Maintain Idelalisib dosing. Monitor ANC at least weekly</td>
<td>Interrupt Idelalisib dosing. Monitor ANC at least weekly until ANC ≥ 0.5x10^9/L, then may resume Idelalisib dosing at 100 mg twice daily</td>
</tr>
</tbody>
</table>

Renal impairment:
No dose adjustment is required for patients with mild, moderate, or severe renal impairment.

Hepatic dysfunction:
No dose adjustment is required when initiating treatment with idelalisib in patients with mild or moderate hepatic impairment, but intensified monitoring of LFTS is recommended.

There is insufficient data to make dose recommendations for patients with severe hepatic impairment. Therefore, caution is recommended when administering idelalisib in this population and intensified LFT monitoring for adverse effects is recommended.
Elevated liver transaminases:
Table 1: Management of elevated transaminases

<table>
<thead>
<tr>
<th>ALT / AST</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 3-5 x ULN</td>
<td>Increase monitoring of LFTs including AST to weekly until the values fall to ≤ 3 x ULN.</td>
</tr>
<tr>
<td>First occurrence &gt; 5 x ULN</td>
<td>Withhold treatment with idelalisib until ALT/AST ≤ 3 x ULN. Treatment can then be resumed at 100mg twice daily. If this event does not recur at 100mg twice daily, the dose can be increased to 150mg twice daily again, at the discretion of the prescribing Consultant.</td>
</tr>
<tr>
<td>Second occurrence &gt; 5 x ULN</td>
<td>Withhold idelalisib until ALT/AST ≤ 3 x ULN. Re-initiation at 100mg twice daily may be considered at the discretion of the prescribing Consultant.</td>
</tr>
</tbody>
</table>

Table 2: Management of idelalisib treatment related diarrhoea/colitis (2)

<table>
<thead>
<tr>
<th>Diarrhoea</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1-2</td>
<td>No dose modification recommended. Usually responsive to common antidiarrhoeal agents (Refer to Coutre et al for more detailed information (2))</td>
</tr>
<tr>
<td>Unresolved grade 2 and Grade ≥ 3 Diarrhoea/colitis</td>
<td>Initial management should include diagnostic testing to rule out infectious causes. After exclusion of infectious causes, initiation of budesonide oral or intravenous steroid therapy is recommended. The duration of treatment should be based on individual clinical response. Withhold treatment with idelalisib until diarrhoea/colitis resolved to ≤ Grade 1. Resume treatment at 100mg BD per clinical judgement.</td>
</tr>
</tbody>
</table>
Table 3: Dose modification schedule based on adverse events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Discontinue</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonitis</td>
<td>Discontinue</td>
<td>Treatment with idelalisib must be withheld in the event of suspected pneumonitis. Once pneumonitis has resolved and if re-treatment is appropriate, resumption of treatment at 100 mg twice daily can be considered.</td>
</tr>
<tr>
<td>Grade ≥ 3 Rash</td>
<td>Discontinue</td>
<td>Withhold treatment until resolved to ≤ Grade 1. Resume treatment at 100mg BD. If rash does not recur, the dose may be escalated to 150mg BD at the discretion of the prescribing consultant.</td>
</tr>
<tr>
<td>Intestinal perforation</td>
<td>Discontinue</td>
<td>Treatment with idelalisib must be withheld.</td>
</tr>
</tbody>
</table>

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:** Minimal (Refer to local policy).

**PREMEDICATIONS:** None usually required

**TAKE HOME MEDICATIONS:**
- Tumour cell lysis prophylaxis (Refer to local policy)
- PJP prophylaxis (Refer to local policy)
- Antiviral prophylaxis (Refer to local policy)
- Antifungal prophylaxis (Refer to local policy)

**OTHER SUPPORTIVE CARE:**
- Women of childbearing potential must use highly effective contraception while taking idelalisib and for 1 month after stopping treatment.
- Women using hormonal contraceptives should add a barrier method as a second form of contraception since it is currently unknown whether idelalisib may reduce the effectiveness of hormonal contraceptives.

**ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS**

This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE’s terms of use available at [http://www.hse.ie/eng/Disclaimer](http://www.hse.ie/eng/Disclaimer)

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoprotocols](http://www.hse.ie/NCCPchemoprotocols)
• **Diarrhoea/Colitis**: Cases of severe drug-related colitis occurred relatively late (on average 6 months after initiation of treatment but resolved within a few weeks with dose interruption and specific treatment. Please refer to Coutre SE, et al. “Management of adverse events associated with idelalisib treatment-expert panel opinion” (2) for detailed information on management. The recommended management is summarized in Table 2. There is very limited experience from the treatment of patients with a history of inflammatory bowel disease.

• **Pneumonitis**: Any patient presenting with pulmonary symptoms such as cough, dyspnoea, hypoxia, interstitial infiltrates on a radiologic examination or a decline in oxygen saturation by > 5% should be evaluated for pneumonitis. If pneumonitis is suspected, idelalisib should be interrupted until the cause is determined. Treatment with idelalisib must be discontinued for moderate or severe symptomatic pneumonitis.

• **All patients should receive prophylaxis for PJP during treatment with idelalisib**. This should be continued for 2-6 months after discontinuation of idelalisib. The duration of post-treatment prophylaxis should be based on clinical judgement.

• **CMV infection**: Regular clinical and lab monitoring for CMV infection is recommended in patients who are CMV-seropositive at the start of treatment with idelalisib or have other evidence of a history of CMV infection. Patients with CMV viraemia even without signs of CMV infection should be treated with appropriate anti-CMV therapy. For patients with evidence of CMV viraemia and clinical signs of CMV infection, treatment with idelalisib should be stopped. Idelalisib may be restarted if the infection has resolved and the benefits of resuming are judged to outweigh the risks. If re-started, pre-emptive CMV therapy should be considered.

**DRUG INTERACTIONS:**

• Avoid co-administration with moderate or strong CYP3A inducers as this may result in reduced plasma concentrations of idelalisib.

• The primary metabolite of idelalisib, GS-563117, is a strong CYP3A4 inhibitor, and so the concomitant use of idelalisib with medicinal products metabolised by CYP3A may lead to increased serum concentrations of the other product.

• Current drug interaction databases should be consulted for more information.
ATC CODE:  
Idelalisib  
L01XX47

REIMBURSEMENT CATEGORY:  
Idelalisib is available for reimbursement, for this indication, under the High Tech Arrangements on the PCRS drug reimbursement schemes (January 2017).

PRESCRIPTIVE AUTHORITY:  
The treatment plan must be initiated by a Consultant Haematologist working in the area of haematological malignancies

REFERENCES:  

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>05/01/2017</td>
<td></td>
<td>Prof Elisabeth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Vandenberghe</td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer.  
This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols.